Roche Holding AG (OTCMKTS:RHHBY) Stock Has Average Target Price of $60.00

Roche Holding AG (OTCMKTS:RHHBY) has received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $60.00.

Several research firms have recently issued reports on RHHBY. HSBC reaffirmed a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Morgan Stanley upgraded shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price target on the stock in a report on Friday, August 7th. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Finally, Royal Bank Of Canada initiated coverage on Roche in a report on Tuesday, September 8th. They issued an “outperform” rating for the company.

Institutional Investors Weigh In On Roche

A number of institutional investors have recently made changes to their positions in the stock. Opal Capital LLC acquired a new position in shares of Roche in the first quarter worth approximately $4,448,000. S&CO Inc. boosted its holdings in Roche by 163.0% in the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after acquiring an additional 87,107 shares during the last quarter. North Star Asset Management Inc. acquired a new stake in Roche during the 2nd quarter valued at approximately $1,351,000. Puzo Michael J acquired a new stake in Roche during the 2nd quarter valued at approximately $1,229,000. Finally, Woodstock Corp acquired a new position in shares of Roche in the 3rd quarter worth approximately $245,000.

Roche Trading Up 0.6%

Roche stock opened at $57.14 on Tuesday. The business has a 50 day moving average of $54.86 and a 200-day moving average of $52.77. Roche has a 1 year low of $40.07 and a 1 year high of $60.85. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.69.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.